z-logo
open-access-imgOpen Access
Molecular Docking Study from Lunacridine, Scopoletin and Skimmianine as Antidiabetes through α-Glucosidase Inhibitor
Author(s) -
Adriani,
Noorhamdani,
Sri Winarsih,
Tri Ardyati
Publication year - 2019
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1374/1/012026
Subject(s) - scopoletin , acarbose , docking (animal) , enzyme , biochemistry , computational biology , pharmacology , chemistry , biology , medicine , alternative medicine , nursing , pathology
Diabetes is a metabolic syndrome disease characterized by hyperglycemia in patients. The use of medicinal plants for the treatment of diabetes can control blood levels because it contains anti-diabetic active substances. The medicinal plant as an anti-diabetic through inhibition of the α-glucosidase enzyme thereby reducing the absorption of glucose in the small intestine. Lunacridine, skimmianine and scopoletin are found in the Rutaceae family but there is no information about them as α-glucosidase inhibitors. The purpose of the study to determine the ability of lunacridine, skimmianine and scopoletin as inhibitors of α-glucosidase enzymes based on docking molecular studies. The research method is ligand and receptor preparation using Pymol and docking. The docking process uses Autodoct vina in Pyrx and using acarbose as controls. The docking results are visualized using Ligplot and Discovery studio software. The results showed that lunacridine, skimmianine, scopoletin interacted with α-glucosidase and various binding affinity value. The lunacridine binding affinity is close to the acarbose control and can cross cell membranes based on Lipinski rules. Lunacridine has an anti-diabetic ability through inhibition of α-glucosidase enzyme with the inhibitory value close to acarbose control.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here